Umbilical cord stem cells: what peer-reviewed analyses say about commercial products

How 'stem cell' is defined in the peer-reviewed literature

The International Society for Cell & Gene Therapy (ISCT) published minimal criteria in 2006 for what counts as a multipotent mesenchymal stromal cell: plastic adherence under standard culture conditions, expression of specific surface markers including CD73, CD90, and CD105 alongside the absence of hematopoietic markers, and demonstrated tri-lineage differentiation into bone, cartilage, and fat cell types in culture. These criteria exist because 'stem cell' on its own is not a precise laboratory description; it is a functional claim that has to be demonstrated, not assumed from tissue of origin.

A product derived from umbilical cord tissue does not automatically meet these criteria simply because umbilical cord tissue is a documented research source of mesenchymal stromal cells in some settings. Whether cells in a specific commercial preparation satisfy the ISCT minimal criteria is an empirical question that depends on how the tissue was processed, how long it was stored, and what condition the cells were in at the time of testing.

What peer-reviewed analyses have found in commercial umbilical cord products

A 2026 analysis examined six commercial Wharton's jelly products and reported low total cell counts and low cell viability, with only rare viable mesenchymal stromal cells identified across the products tested. A separate 2021 study examining five commercial umbilical cord allograft products found no colony-forming mesenchymal stromal cells in any of them, meaning none of the five produced the adherent, expanding cell colonies that serve as a standard functional test for stromal cell presence.

Published evidence on Wharton's jelly biologics more broadly is described as early-stage and largely based on small studies, and the material itself is understood as a gelatinous connective tissue matrix rich in hyaluronic acid, collagens, and growth factors rather than as a cell therapy in the clinical sense. Together, these findings indicate that, across the eleven products studied, documentation did not establish the viable, functionally confirmed stem cell content that the term implies; they do not establish results for every commercial product.

Why 'umbilical cord stem cells' is not supported as a product label

Given the colony-forming and viability findings described above, referring to a commercial Wharton's jelly allograft as a 'stem cell' product is not supported by the documentation available for the products studied. We describe our WJ products as perinatal tissue allografts, not stem cell products. Review any cell-content data separately.

This distinction is not just semantic. Marketing or clinical materials that use 'stem cell therapy' language for a product that has not been shown to contain viable, functional stem cells create a gap between what is claimed and what the documentation supports, a pattern FDA has specifically flagged in recent warning letters to distributors in this category.

What this means for sourcing and documentation decisions

Buyers evaluating a Wharton's jelly or umbilical cord-derived product should request cell count and viability data tied to the specific lot being purchased, rather than relying on category-level assumptions about what cord tissue 'should' contain. A certificate of analysis that addresses sterility and release testing does not necessarily address cell content or viability unless it says so explicitly.

These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice. Questions about how a specific product should be described in clinical or marketing materials belong with a medical director and regulatory counsel.

• Ask whether the supplier reports cell count and viability per lot, and against which method
• Ask whether colony-forming or tri-lineage differentiation testing has been performed, and on what
• Compare marketing language against what the lot documentation actually supports
• Confirm internal and patient-facing materials describe the product by composition, not by an unverified cell-content claim